{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:23:49Z","timestamp":1782512629722,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.clinthera.2012.09.008","type":"journal-article","created":{"date-parts":[[2012,9,29]],"date-time":"2012-09-29T23:50:35Z","timestamp":1348962635000},"page":"2051-2060","source":"Crossref","is-referenced-by-count":14,"title":["Dabigatran in Clinical Practice"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct01452347","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rangadham","family":"Nagarakanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.09.008_bib1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.amjcard.2009.10.018","article-title":"Thromboembolism in atrial fibrillation","volume":"105","author":"Menke","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2012.09.008_bib2","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2012.09.008_bib3","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.09.008_bib4","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.09.008_bib5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2012.09.008_bib6","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jacc.2010.09.013","volume":"57","author":"Fuster","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2012.09.008_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2010.10.001","article-title":"2011 ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"57","author":"Wann","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2012.09.008_bib8","doi-asserted-by":"crossref","first-page":"e120S","DOI":"10.1378\/chest.11-2294","article-title":"New anticoagulant drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical; practice guidelines","volume":"141","author":"Weitz","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2012.09.008_bib9","series-title":"Pradaxa (dabigatran etexilate mesylate) capsules","year":"2012"},{"key":"10.1016\/j.clinthera.2012.09.008_bib10","author":"Wood"},{"key":"10.1016\/j.clinthera.2012.09.008_bib11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.09.008_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.09.008_bib13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.09.008_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2012.09.008_bib15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2013a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.09.008_bib16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2012.09.008_bib17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2012.09.008_bib18","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.09.008_bib19","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.09.008_bib20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","article-title":"Dabigatran etexilate: a new oral thrombin inhibitor","volume":"123","author":"Hankey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2012.09.008_bib21","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2012.09.008_bib22","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2012.09.008_bib23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-155-10-201111150-00004","article-title":"Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial","volume":"155","author":"Oldgren","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2012.09.008_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2012.09.008_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.09.008_bib26","first-page":"148","article-title":"Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate","volume":"93","author":"Van Ryn","year":"2008","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.09.008_bib27","first-page":"A94","article-title":"Beriplex P\/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits","volume":"37","author":"van Ryn","year":"2010","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.clinthera.2012.09.008_bib28","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2012.09.008_bib29","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2012.09.008_bib30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1160\/TH11-01-0042","article-title":"Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran","volume":"106","author":"Matute","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2012.09.008_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1159\/000319886","article-title":"Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran","volume":"30","author":"De Smedt","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.clinthera.2012.09.008_bib32","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1345\/aph.1Q105","article-title":"Potential inaccuracy of point-of-care INR in dabigatran-treated patients","volume":"45","author":"Baruch","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2012.09.008_bib33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1540-8167.2011.02175.x","article-title":"The use of dabigatran immediately after atrial fibrillation ablation","volume":"23","author":"Winkle","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.clinthera.2012.09.008_bib34","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.amjcard.2005.01.049","article-title":"Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials","volume":"95","author":"Serebruany","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2012.09.008_bib35","first-page":"632","article-title":"Cytochrome P450 enzymes and genotype-guided drug therapy","volume":"11","author":"Roederer","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.clinthera.2012.09.008_bib36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","article-title":"Drug and dietary interactions of warfarin and novel oral anticoagulants: an update","volume":"31","author":"Nutescu","year":"2011","journal-title":"J Thromb Thrombolysis"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2012.09.008_bib37","first-page":"618","article-title":"Pharmacokinetic and pharmacodynamic interaction of dronedarone and dabigatran in healthy subjects (abstract P3566)","volume":"32","author":"Brunet","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2012.09.008_bib38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.amjmed.2011.10.017","article-title":"Interpretation of point-of-care INR results in patients treated with dabigatran","volume":"125","author":"van Ryn","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2012.09.008_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MBC.0b013e32834f1b0c","article-title":"Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran","volume":"23","author":"Stangier","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.clinthera.2012.09.008_bib40","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0735-1097(11)61130-3","article-title":"Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models","volume":"57","author":"van Ryn","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2012.09.008_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/STROKEAHA.111.622498","article-title":"Using dabigatran in patients with stroke: a practical guide for clinicians","volume":"43","author":"Alberts","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2012.09.008_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation","volume":"154","author":"Freeman","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2012.09.008_bib44","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1161\/STROKEAHA.111.641027","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack","volume":"43","author":"Kamel","year":"2012","journal-title":"Stroke"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812005309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812005309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T11:57:18Z","timestamp":1542715038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812005309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0149291812005309"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.09.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}